-
公开(公告)号：EP1583518A1
公开(公告)日：2005-10-12
申请号：EP03702432.0
申请日：2003-01-06
发明人： PFEIFFER, Indriati,Department of Applied Physics , HÖÖK, Fredrik,Departement of Applied Physics , SVEDHEM, Sofia,Departement of Applied Physics , LARSSON, Charlotte,Departement of Applied Physics , CARLSSON, Roland
CPC分类号： G01N33/5432 , C12Q1/6816 , C12Q1/6837 , C12Q2563/161
摘要： The present invention relates to a use of a lipid vesicle having bound thereto a targeting polynucleotide and a protein, polypeptide or peptide, which targeting polynucleotide is complementary to a region of a scaffold polynucleotide, to spatially distribute the protein, polypeptide or peptide at a defined position relative to the scaffold polynucleotide.
摘要翻译： 本发明涉及具有与其结合的靶向多核苷酸和蛋白质，多肽或肽的脂质囊泡的用途，所述靶向多核苷酸与支架多核苷酸的区域互补，以空间分布所定义的蛋白质，多肽或肽 相对于支架多核苷酸的位置。
-
公开(公告)号：EP0988378B1
公开(公告)日：2003-11-26
申请号：EP98901380.0
申请日：1998-01-26
CPC分类号： C12N15/102 , C07K16/00 , C07K16/44 , C07K2317/622 , C07K2317/92 , C12N15/1027 , C12N15/1031 , C12N15/1058 , C12N15/1086 , Y10T436/143333
-
公开(公告)号：EP1268801A2
公开(公告)日：2003-01-02
申请号：EP01925538.9
申请日：2001-04-04
发明人： OHLIN, Mats , SODERLIND, Eskil , CARLSSON, Roland
CPC分类号： C12N15/1058 , C07K16/00 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C40B10/00
摘要： The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the 'master framework'), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the 'original framework'), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.
-
公开(公告)号：EP0805877B1
公开(公告)日：2001-08-16
申请号：EP96901168.3
申请日：1996-01-15
CPC分类号： C40B40/02 , C12N15/1037
摘要： An improved method for selecting a molecule such as an antibody, antigen, peptide, protein or fragment thereof and its encoding sequence, which molecule is expressed together with a phage coat protein on the phages surface. The improvement is achieved through a new mutant filamentous helper phage which has retained the gene III promoter, whereas the gene III encoding sequence is deleted. Amplification of phage titer of 10 times were achieved in M13-derived phages, when used for the selection of specific antibody.
-
公开(公告)号：EP0805877A1
公开(公告)日：1997-11-12
申请号：EP96901168.0
申请日：1996-01-15
CPC分类号： C40B40/02 , C12N15/1037
摘要： An improved method for selecting a molecule such as an antibody, antigen, peptide, protein or fragment thereof and its encoding sequence, which molecule is expressed together with a phage coat protein on the phages surface. The improvement is achieved through a new mutant filamentous helper phage which has retained the gene III promoter, whereas the gene III encoding sequence is deleted. Amplification of phage titer of 106 times were achieved in M13-derived phages, when used for the selection of specific antibody.
-
66.发明授权METHOD FOR THE REMOVAL OF UNDESIRED CELLS FROM HUMAN LYMPHOCYTE POPULATIONS, APPLICATION OF THE METHOD IN MONOCLONAL ANTIBODY PRODUCTION AND KIT THEREFOR 失效从人类淋巴细胞群体中去除未细胞细胞的方法，该方法在单克隆抗体生产中的应用及其应用
公开(公告)号：EP0342188B1
公开(公告)日：1993-07-21
申请号：EP87906018.4
申请日：1987-09-01
CPC分类号： C12N5/0087 , C12N5/163
摘要： A method for the removal of, for in vitro immunisation, undesired cells from human lymphocyte containing cell populations. For the method, use is made of lysosomotropic agents which are caused to act in vitro on human lymphocyte containing cell populations. Also disclosed is a method in the in vitro immunisation of lymphocytes for use in the production of human monoclonal antibodies. In this method, lysosomotropic agents are caused to act in vitro on human lymphocyte containing cell populations for removing cell populations having a negative effect on the in vitro immunisation, whereupon the lymphocytes are in vitro immunised antigen-specifically and immortalised. Finally, a kit for in vitro immunisation of lymphocytes for use in the production of human monoclonal antibodies is disclosed. The kit comprises as active constituents a container containing lymphokines and a container containing lysosomotropic agents.
-
-
-
-
-
搜索结果
66 条记录 (耗时 0.012 秒)
